Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 14/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380713 | 1.00 | USP2 (0.41) | USP2TACR2CYP3A4HSD17B10TSHR | |
| SCHEMBL4631280 | 0.92 | TACR2 (0.49) | USP2TACR2CYP3A4HSD17B10TSHR | |
| SCHEMBL380927 | 0.90 | USP2 (0.40) | USP2CYP3A4HSD17B10TSHRCYP2C9 | |
| SCHEMBL380926 | 0.90 | USP2 (0.40) | USP2CYP3A4HSD17B10TSHRCYP2C9 | |
| SCHEMBL4864462 | 0.88 | USP2 (0.42) | USP2CYP3A4HSD17B10TSHRCYP2C9 | |
| SCHEMBL5115024 | 0.88 | USP2 (0.42) | USP2CYP3A4HSD17B10TSHRCYP2C9 | |
| SCHEMBL5106731 | 0.83 | TACR2 (0.39) | USP2TACR2CYP3A4TSHRCYP2C9 | |
| SCHEMBL768895 | 0.82 | RORC (0.41) | USP2TACR2CYP3A4HSD17B10TSHR | |
| SCHEMBL768894 | 0.82 | RORC (0.41) | USP2TACR2CYP3A4HSD17B10TSHR | |
| SCHEMBL4631148 | 0.79 | TACR2 (0.46) | USP2TACR2CYP3A4HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | USP2 2694/4885TACR2 3/4885CYP3A4 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.